Drug Trial Radar · NCT07822880
A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Oct 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Sep 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety of selpercatinib in participants with RET-altered cancers in India. The study will also assess the number of changes and why participants stop study treatment. For each participant, the study is expected to last 56 weeks and will include up to 16 protocol-specific visits.
Conditions
- Thyroid Neoplasms
- Carcinoma, Non-Small-Cell Lung
Interventions
SelpercatinibDrug
Tablet administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Treatment Emergent Adverse Event(s) (TEAEs)Time frame: Cycle 1 Day 1, End of Study (approximately 56 weeks) (Cycle = 28 days)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
The Gujarat Cancer & Research Institute (GCRI)
Ahmedabad, India
SRV Hospitals
Bengaluru, India
AIIMS, Bhubaneshwar
Bhubaneswar, India
Aadhar Health Institute
Hisar, India
Ruby General Hospital Pvt. Ltd
Kolkata, India
Government Medical College, Kozhikode
Kozhikode, India
Mumbai Oncocare Center
Mumbai (E), India
Institute Rotary Cancer Hospital
New Delhi, India
Vardhman Mahavir Medical College & Safdarjung Hospital
New Delhi, India
MPMMCC(Mahamana Cancer Hospital)
Varanasi, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.